The global diabetes clinical trials market size was estimated at USD 5.1 billion in 2025 and is projected to reach USD 9.3 billion by 2033, growing at a CAGR of 7.9% from 2026 to 2033. The market is witnessing significant growth as the burden of diabetes continues to rise across both developed and emerging economies. Increasing prevalence of diabetes and its associated complications has intensified the need for innovative treatment approaches, encouraging pharmaceutical and biotechnology companies to expand their clinical research activities. As healthcare systems face mounting pressure to manage long-term diabetes-related complications, clinical trials have become essential for evaluating the safety and efficacy of next-generation therapies. Growing expansion of clinical trials and rising R&D investments are further strengthening the market outlook, creating opportunities for new drug development and advanced disease management strategies.

In addition to the growing patient population, several demographic and lifestyle-related factors are accelerating market growth. Sedentary lifestyles, an aging population, and changes in dietary habits have contributed significantly to the increasing incidence of diabetes worldwide. These trends have created an urgent demand for more effective therapeutic solutions capable of improving patient outcomes and reducing healthcare costs. Clinical trials play a critical role in addressing these challenges by supporting the development of novel medications, disease-modifying therapies, and precision medicine approaches. As stakeholders continue to prioritize diabetes research, the industry is expected to witness sustained investment and innovation throughout the forecast period.

Download a free sample copy of the Diabetes Clinical Trials market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

·         North America diabetes clinical trials market held the largest share of 50.8% of the global market in 2025. The region's dominance can be attributed to strong healthcare infrastructure, extensive clinical research networks, and the presence of leading pharmaceutical and biotechnology companies actively investing in diabetes drug development.

·         The diabetes clinical trials industry in the U.S. accounted for the highest market share in North America. The country's leadership is supported by advanced research capabilities, a large patient population, favorable regulatory pathways, and significant investments in clinical development programs focused on diabetes treatment and prevention.

·         By phase, the phase III segment held the largest market share of 53.6% in 2025. The dominance of this segment reflects the substantial number of late-stage clinical studies conducted to validate the safety, efficacy, and commercial viability of promising diabetes therapies before regulatory approval.

·         Based on the study design, the interventional trials segment held the largest market share in 2025. Interventional studies remain the preferred approach for evaluating new drugs, treatment combinations, and innovative therapeutic strategies aimed at improving diabetes management and patient outcomes.

·         By indication, the type 2 diabetes mellitus (T2DM) segment held the largest revenue share in 2025. The high prevalence of T2DM globally, combined with increasing healthcare awareness and demand for advanced treatment options, continues to drive extensive clinical research activity within this segment.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

Leading companies operating in the market are implementing strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and geographic expansions to strengthen their market positions. These initiatives are enabling organizations to accelerate research timelines, expand clinical trial capabilities, and improve access to innovative therapies.

For instance, in October 2025, Eli Lilly and Company initiated two new clinical studies to evaluate the potential of the drug Baricitinib in delaying the onset and slowing the progression of Type 1 Diabetes. These trial launches build on prior evidence generated from the BANDIT study conducted in Australia, which assessed the drug’s effectiveness in children and young adults recently diagnosed with the condition. The earlier research was supported by Breakthrough T1D through its Type 1 Diabetes Clinical Research Network. The new trials are expected to further validate baricitinib’s role as a disease-modifying therapy, marking a significant step toward early intervention strategies in Type 1 diabetes management. As research efforts continue to advance, such developments are expected to contribute to the evolution of diabetes treatment paradigms and support long-term growth across the diabetes clinical trials market.

Key Diabetes Clinical Trials Companies:

·        Syneos Health

·        Medpace

·        IQVIA

·        ICON plc

·        Fortrea

·        Parexel

·        ProSciento

·        Profil Institut für Stoffwechselforschung

·        Novo Nordisk

·        Eli Lilly and Company

·        Sanofi

·        AstraZeneca

Explore Grand View Horizon to see global and regional level statistics related to the Diabetes Clinical Trials Market

Grand View Research offers

·         Focused market intelligence reports on specific geographies or high-growth segments.

·         Extended forecast timelines for long-term planning.

·         Competitor Benchmarking and Supply Chain Analysis

·         Inclusion of regulatory and policy assessments.

·         Inclusion of custom data models, KPIs, or applications unique to your business

·         Specific high-impact Data Decks and Tables to support effective decision making

·         And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering